Nexstim Plc Publishes 2025 Annual Report
Idag, 11:00
Company announcement, Helsinki, 5 March 2026 at 12 PM (EET)
Nexstim Plc Publishes 2025 Annual Report
Nexstim Plc ("Nexstim" or "Company") announces the publication of its 2025 Annual Report. The annual report is available in English and Finnish under the "Investors" section of the Company's website at nexstim.com/investors/financial-reports-and-presentations.
The Annual Report includes the Report of the Board of Directors, Parent Company and Consolidated Financial Statements as well as the Auditor's Report. A copy of the Annual Report is attached to this announcement.
NEXSTIM PLC
Mikko Karvinen, CEO
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB.
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
AttachmentsNexstim Plc_Company announcement_AR 2025_05032026_EN_FINAL.pdfNexstim-AR25-EN-FINAL.pdf
Ämnen i artikeln
Nexstim Plc Publishes 2025 Annual Report
Idag, 11:00
Company announcement, Helsinki, 5 March 2026 at 12 PM (EET)
Nexstim Plc Publishes 2025 Annual Report
Nexstim Plc ("Nexstim" or "Company") announces the publication of its 2025 Annual Report. The annual report is available in English and Finnish under the "Investors" section of the Company's website at nexstim.com/investors/financial-reports-and-presentations.
The Annual Report includes the Report of the Board of Directors, Parent Company and Consolidated Financial Statements as well as the Auditor's Report. A copy of the Annual Report is attached to this announcement.
NEXSTIM PLC
Mikko Karvinen, CEO
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB.
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
AttachmentsNexstim Plc_Company announcement_AR 2025_05032026_EN_FINAL.pdfNexstim-AR25-EN-FINAL.pdf
Ämnen i artikeln
-992x558.webp&w=3840&q=75)
Analys
Börser
Analys
Börser
Marknadsöversikt
1 DAG %
Senast
1 mån
